Hummingbird Bioscience: an agile start-up takes to the skies

Hummingbird Bioscience is a highly innovative biotech company founded in 2014 to leverage the power of systems biology so as to transform oncology drug discovery and development. Harnessing its proprietary rational antibody discovery platform and supported by deep experience in integrative genomics as well as proteomics strategies, Hummingbird develops precision therapeutic antibodies for patients with the highest unmet need. With facilities in Singapore and South San Francisco, the company has built a pipeline of oncology and immuno-oncology drug candidates, and will start clinical trials at the end of 2019. Biotech Connection Singapore spoke to Dr. Piers Ingram (PI), co-founder and CEO of Hummingbird Bioscience to find out how the start-up spreads its wings and flies. The bee hummingbird (Mellisuga helenae) is the smallest bird in the world. Why did you name yourselves after a small bird? PI: Firstly, it is a unique name for an agile and nimble company. The…

Singapore Life Science Case Competition

The Singapore Life Science Case Competition, the first of its kind, is a business case competition focused on the life sciences and pharmaceutical industries. Put together by Biotech Connection Singapore, L.E.K. Consulting and ESSEC Business School, this competition is open to all university students, postgraduates, researchers and biotech/medtech entrepreneurs.

Translational Diabetes

In Singapore, there are over 400,000 people living with diabetes. Patients can develop complications, including cardiovascular disease, kidney disease, eye problems and foot ulcers. Diabetes cost Singapore more than S$1 billion in 2010 and is expected to soar to more than S$2.5 billion by 2050. Translational medicine is central to the goal of converting basic discoveries to diagnostic and therapeutic tools that can be harnessed to treat diseases and improve human health. In this panel discussion organized with the Eureka Institute of Translational Medicine on 7 August 2018, we focused on translational opportunities in diabetes.

IGNite: A Fireside Chat with Dr. Murray Robinson, CSO of MediSix Therapeutics

Innovators Gathering Night (IGNite), is a series of fireside chats with biotech and medtech innovators to find out what ignites their passion to innovate within their fields. It is also a platform for current and future innovators to meet and network, and ignite conversations leading to collaborative opportunities. In our first IGNite event on 12 July 2018, jointly organised by BCS and A*START Central, we invited Dr. Murray Robinson, Chief Scientific Officer of MediSix Therapeutics, to join us for a fireside chat to find out what ignites his passion in the biotech field and how he embarked on his journey in innovation and entrepreneurship.

An exclusive interview with Esco – from cleanrooms to containment systems

Esco Group is a Singapore-based life science company with a diversified portfolio and sales in over 100 countries. As a leading manufacturer of laboratory and biopharma equipment, as well as IVF medical devices, Esco offers tailored solutions that fit the needs of laboratories. Esco Group provides equipment and services to support cutting-edge research as well as commercial manufacturing of biopharmaceuticals in the Life Sciences, Medical and Healthcare divisions. In an exclusive interview with Esco, Biotech Connection Singapore spoke to Mr. Xiangliang Lin (XL Lin), Founder & CEO of Esco Aster, an independent Contract Development and Manufacturing Organization (CDMO) in the Esco Group of companies.What is the mission which drives Esco and its spin-offs? XL Lin: Regardless of what we do, the intrinsic mission of Esco is to invent, discover and commercialize enabling technologies to make human lives healthier and safer. For example, our biological safety cabinets (BSCs) and…